- Home
- VIVK vs INKT Comparison
VIVK vs INKT Comparison
Compare VIVK & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVK
- INKT
- Stock Information
- Founded
- VIVK 2006
- INKT 2017
- Country
- VIVK United States
- INKT United States
- Employees
- VIVK N/A
- INKT N/A
- Industry
- VIVK Oilfield Services/Equipment
- INKT Medicinal Chemicals and Botanical Products
- Sector
- VIVK Energy
- INKT Health Care
- Exchange
- VIVK Nasdaq
- INKT Nasdaq
- Market Cap
- VIVK 34.9M
- INKT 31.2M
- IPO Year
- VIVK N/A
- INKT 2021
- Fundamental
- Price
- VIVK $0.84
- INKT $7.14
- Analyst Decision
- VIVK
- INKT Strong Buy
- Analyst Count
- VIVK 0
- INKT 2
- Target Price
- VIVK N/A
- INKT $37.50
- AVG Volume (30 Days)
- VIVK 1.7M
- INKT 5.5K
- Earning Date
- VIVK 05-20-2025
- INKT 05-15-2025
- Dividend Yield
- VIVK N/A
- INKT N/A
- EPS Growth
- VIVK N/A
- INKT N/A
- EPS
- VIVK N/A
- INKT N/A
- Revenue
- VIVK $111,130,140.00
- INKT N/A
- Revenue This Year
- VIVK N/A
- INKT N/A
- Revenue Next Year
- VIVK N/A
- INKT N/A
- P/E Ratio
- VIVK N/A
- INKT N/A
- Revenue Growth
- VIVK 85.84
- INKT N/A
- 52 Week Low
- VIVK $0.55
- INKT $4.56
- 52 Week High
- VIVK $3.45
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- VIVK 58.19
- INKT 47.31
- Support Level
- VIVK $0.71
- INKT $6.89
- Resistance Level
- VIVK $1.27
- INKT $7.25
- Average True Range (ATR)
- VIVK 0.09
- INKT 0.42
- MACD
- VIVK 0.03
- INKT 0.01
- Stochastic Oscillator
- VIVK 51.22
- INKT 39.70
About VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.